Pharsight

1. List of Namzaric drug patents

Application	Filing Date	Opposition Party	Legal Status
EP05852057A	2013-12-21	Elend, Almut Susanne	Revoked
EP06749777A	2011-06-10	Merz Pharma GmbH & Co. KGaA	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8362085	December, 2014	Terminated-Denied	Adamas Pharmaceuticals, Inc.	Ranbaxy, Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338485	ALLERGAN	Compositions for the treatment of CNS-related conditions	Nov, 2025 (2 years from now)
US8173708	ALLERGAN	Method and composition for administering an NMDA receptor antagonist to a subject	Nov, 2025 (2 years from now)
US8362085	ALLERGAN	Method for administering an NMDA receptor antagonist to a subject	Nov, 2025 (2 years from now)
US8338486	ALLERGAN	Methods for the treatment of CNS-related conditions	Nov, 2025 (2 years from now)
US8283379	ALLERGAN	Methods and compositions for the treatment of CNS-related conditions	Nov, 2025 (2 years from now)
US8580858	ALLERGAN	Compositions for the treatment of CNS-related conditions	Nov, 2025 (2 years from now)
US8329752	ALLERGAN	Composition for administering an NMDA receptor antagonist to a subject	Nov, 2025 (2 years from now)
US8598233	ALLERGAN	Method for administering an NMDA receptor antagonist to a subject	Nov, 2025 (2 years from now)
US8168209	ALLERGAN	Method and composition for administering an NMDA receptor antagonist to a subject	Nov, 2025 (2 years from now)
US8293794	ALLERGAN	Methods and compositions for the treatment of CNS-related conditions	Nov, 2025 (2 years from now)
US8168209 (Pediatric)	ALLERGAN	Method and composition for administering an NMDA receptor antagonist to a subject	May, 2026 (2 years from now)
US8598233 (Pediatric)	ALLERGAN	Method for administering an NMDA receptor antagonist to a subject	May, 2026 (2 years from now)
US8329752 (Pediatric)	ALLERGAN	Composition for administering an NMDA receptor antagonist to a subject	May, 2026 (2 years from now)
US8173708 (Pediatric)	ALLERGAN	Method and composition for administering an NMDA receptor antagonist to a subject	May, 2026 (2 years from now)
US8362085 (Pediatric)	ALLERGAN	Method for administering an NMDA receptor antagonist to a subject	May, 2026 (2 years from now)
US8283379 (Pediatric)	ALLERGAN	Methods and compositions for the treatment of CNS-related conditions	May, 2026 (2 years from now)
US8039009	ALLERGAN	Modified release formulations of memantine oral dosage forms	Mar, 2029 (5 years from now)
US8039009 (Pediatric)	ALLERGAN	Modified release formulations of memantine oral dosage forms	Sep, 2029 (6 years from now)
US8058291	ALLERGAN	Methods and compositions for the treatment of CNS-related conditions	Dec, 2029 (6 years from now)

Do you want to check out NAMZARIC patents from before 2022?

Market Authorisation Date: 23 December, 2014

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
14 mg/10 mg and 28 mg/10 mg	18 May, 2015	1	27 Jan, 2017	05 Dec, 2029	Eligible
21 mg/10 mg	23 Sep, 2016	1		05 Dec, 2029
7 mg/10 mg	26 Sep, 2016	1		05 Dec, 2029	Extinguished

Strength	Dosage	Availability
10MG;7MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG;14MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG;21MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
10MG;28MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription